- Home
- SKYE vs SGA Comparison
SKYE vs SGA Comparison
Compare SKYE & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SGA
- Stock Information
- Founded
- SKYE 2012
- SGA 1986
- Country
- SKYE United States
- SGA United States
- Employees
- SKYE N/A
- SGA N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SGA Broadcasting
- Sector
- SKYE Health Care
- SGA Consumer Discretionary
- Exchange
- SKYE Nasdaq
- SGA Nasdaq
- Market Cap
- SKYE 101.3M
- SGA 84.1M
- IPO Year
- SKYE N/A
- SGA 1992
- Fundamental
- Price
- SKYE $3.29
- SGA $13.30
- Analyst Decision
- SKYE Buy
- SGA
- Analyst Count
- SKYE 7
- SGA 0
- Target Price
- SKYE $15.50
- SGA N/A
- AVG Volume (30 Days)
- SKYE 313.7K
- SGA 4.4K
- Earning Date
- SKYE 08-07-2025
- SGA 08-07-2025
- Dividend Yield
- SKYE N/A
- SGA 7.58%
- EPS Growth
- SKYE N/A
- SGA N/A
- EPS
- SKYE N/A
- SGA 0.33
- Revenue
- SKYE N/A
- SGA $110,350,000.00
- Revenue This Year
- SKYE N/A
- SGA N/A
- Revenue Next Year
- SKYE N/A
- SGA $4.84
- P/E Ratio
- SKYE N/A
- SGA $40.60
- Revenue Growth
- SKYE N/A
- SGA N/A
- 52 Week Low
- SKYE $1.14
- SGA $10.75
- 52 Week High
- SKYE $7.47
- SGA $15.29
- Technical
- Relative Strength Index (RSI)
- SKYE 44.67
- SGA 54.50
- Support Level
- SKYE $3.23
- SGA $12.10
- Resistance Level
- SKYE $3.75
- SGA $13.46
- Average True Range (ATR)
- SKYE 0.30
- SGA 0.43
- MACD
- SKYE -0.02
- SGA 0.04
- Stochastic Oscillator
- SKYE 29.76
- SGA 85.11
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.